A 12 week study to assess the efficacy and safety of AF-219 in patients with long term cough

Registry ID

EUCTR2015-005064-42

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Afferent Pharmaceuticals, Inc.

Start date

2016-01-15

Completion date

2016-11-04

Last update

2026-08-16

Conditions

• Chronic Cough

Summary

To evaluate the effectiveness of 3 doses of AF-219, as compared to placebo, after 12 weeks of treatment in reducing awake objective cough frequency

Locations

• , , UK

Related clinical trials

• Biomarkers and Respiratory Omics as New CHildren Opportunities - Study of Clinical Outcomes and Predictivity Evaluation
• Remodelling of the Lower Airways in Chronic Cough
• Finnish Children´s Protracted Cough
• Efficacy of Behavioral Therapy for Chronic Refractory Cough
• An Observational Study Using Novel Questionnaire to Characterize Cough Phenotypes in Patients With Chronic Cough
• Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients

View on source registry